McKone Elizabeth L, Sutton Elsa A, Johnson Geoffrey B, Phillips Ryan M
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Department of Radiology, Nuclear Medicine Division, Mayo Clinic, Rochester, MN 55905, USA.
J Clin Med. 2024 Jan 13;13(2):446. doi: 10.3390/jcm13020446.
Major advances in prostate cancer diagnosis, staging, and management have occurred over the past decade, largely due to our improved understanding of the technical aspects and clinical applications of advanced imaging, specifically magnetic resonance imaging (MRI) and prostate-cancer-specific positron emission tomography (PET). Herein, we review the established utility of these important and exciting technologies, as well as areas of controversy and uncertainty that remain important areas for future study. There is strong evidence supporting the utility of MRI in guiding initial biopsy and assessing local disease. There is debate, however, regarding how to best use the imaging modality in risk stratification, treatment planning, and assessment of biochemical failure. Prostate-cancer-specific PET is a relatively new technology that provides great value to the evaluation of newly diagnosed, treated, and recurrent prostate cancer. However, its ideal use in treatment decision making, staging, recurrence detection, and surveillance necessitates further research. Continued study of both imaging modalities will allow for an improved understanding of their best utilization in improving cancer care.
在过去十年中,前列腺癌的诊断、分期和管理取得了重大进展,这主要归功于我们对先进成像技术(特别是磁共振成像(MRI)和前列腺癌特异性正电子发射断层扫描(PET))的技术层面和临床应用有了更深入的了解。在此,我们回顾这些重要且令人兴奋的技术已确立的效用,以及仍作为未来研究重要领域的争议和不确定领域。有强有力的证据支持MRI在指导初始活检和评估局部疾病方面的效用。然而,关于如何在风险分层、治疗规划和生化失败评估中最佳使用这种成像方式存在争议。前列腺癌特异性PET是一项相对较新的技术,它为新诊断、治疗和复发性前列腺癌的评估提供了巨大价值。然而,其在治疗决策、分期、复发检测和监测中的理想应用需要进一步研究。对这两种成像方式的持续研究将有助于更好地理解它们在改善癌症治疗中的最佳利用方式。